Axovant Sciences Ltd (NYSE:AXON)‘s stock had its “sell” rating reaffirmed by analysts at Chardan Capital in a research note issued to investors on Thursday. They presently have a $8.00 price objective on the biotechnology company’s stock. Chardan Capital’s price objective suggests a potential downside of 62.51% from the company’s current price.

A number of other brokerages also recently weighed in on AXON. BidaskClub upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Cowen and Company restated an “outperform” rating and set a $30.00 price objective on shares of Axovant Sciences in a research report on Wednesday, June 21st. CIBC increased their price objective on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. Oppenheimer Holdings, Inc. increased their price objective on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. Finally, Jefferies Group LLC assumed coverage on shares of Axovant Sciences in a research report on Monday, July 10th. They set a “buy” rating and a $40.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. Axovant Sciences presently has a consensus rating of “Hold” and a consensus price target of $26.05.

Shares of Axovant Sciences (NYSE AXON) opened at 21.34 on Thursday. Axovant Sciences has a 12-month low of $11.01 and a 12-month high of $21.85. The company has a 50 day moving average of $20.44 and a 200-day moving average of $17.12. The company’s market cap is $2.29 billion.

Axovant Sciences (NYSE:AXON) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12). Equities research analysts anticipate that Axovant Sciences will post ($2.36) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Chardan Capital Reiterates “Sell” Rating for Axovant Sciences Ltd (AXON)” was reported by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/16/chardan-capital-reiterates-sell-rating-for-axovant-sciences-ltd-axon.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc raised its position in Axovant Sciences by 20.2% in the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 1,168 shares during the period. Bank of America Corp DE raised its position in Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 2,072 shares during the period. Russell Investments Group Ltd. raised its position in Axovant Sciences by 38.5% in the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after acquiring an additional 2,789 shares during the period. Voya Investment Management LLC bought a new position in Axovant Sciences in the second quarter worth approximately $323,000. Finally, Laurion Capital Management LP bought a new position in Axovant Sciences in the second quarter worth approximately $336,000.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.